NCT03198689View on ClinicalTrials.gov

Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

May 7, 2019

Primary Completion Date

June 7, 2023

Study Completion Date

August 28, 2023

Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
DRUG

Brentuximab Vedotin

Dose 0.6 mg/kg i.v. will be given every 3 weeks for 16 cycles (48 weeks) in addition to standard of care medications for SSc that may include cyclophosphamide, methotrexate, azathioprine, mycophenylate mofetil (MMF, cellcept) and mycophenolic acid (myfortic).

Trial Locations (1)

N6A 4V2

Rheumatology Clinic, St. Joseph's Health Care, London

All Listed Sponsors
collaborator

Seagen Inc.

INDUSTRY

lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

NCT03198689 - Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis | Biotech Hunter | Biotech Hunter